ClinicalTrials.gg
CompletedNCT03682185Updated Jul 26, 2024Results posted

The Healthy Patterns Sleep Study

A Phase 3 interventional study of Attention-Control Condition and Timed Activity Intervention in Dementia, Alzheimer Disease and Circadian Rhythm Disorders, sponsored by University of Pennsylvania. Completed at 1 site in United States. Open to participants aged 18 Years to 110 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-26.

Sponsored by University of Pennsylvania · Phase 3, Interventional, and Supportive care

From the registry’s dates

  • Registered 1 year 11 months after the study started (first participant enrolled May 2016, registered Apr 2018).
Phase
Phase 3
Study type
Interventional
Enrollment
421
Allocation
Randomized
Ages
18 Years to 110 Years
Sex
All
01

Study summary

The Healthy Patterns Study intervention is a home-based activity intervention designed to improve symptoms of circadian rhythm disorders (CRD) and quality of life (QOL) in home-dwelling persons with dementia. We will use a randomized two-group parallel design of 200 people with dementia and their caregivers assigned to intervention or attention control groups.

Read the detailed description

Over 5 million Americans have Alzheimer's disease or a related dementia, a progressive and fatal neurodegenerative condition, affecting close to 15 million family caregivers (CG). Circadian rhythm disorders (CRDs) occur in the majority of persons with dementia and include late afternoon/evening agitation (e.g. sundowning) and irregular sleep-wake rhythms such as daytime hypersomnia, frequent night awakenings, and poor sleep efficiency. CRDs can cause a specific cluster of neuropsychiatric symptoms that occur in over 60 percent of patients with dementia and are associated with increased morbidity and mortality and decreased quality of life. Regulating the circadian system via different types of activity have been shown to alter core clock processes that drive CRD symptoms and suggests that a combination of cognitive, physical, and sensory-based activities, delivered at strategic times, may be an effective mechanism to reduce neuropsychiatric symptoms, decrease sleep disruptions, and enhance quality of life for both the care receiver and the caregiver.

Specific components of this brief, one-month, eight sessions, home-based intervention include: 1) assessing PWD health/functional status and preferences/interests; 2) educating caregivers on environmental cues to promote activity and sleep; and 3) training of caregivers in using timed morning, afternoon, and evening activities based on circadian needs across the day.

02

Conditions studied

  • Dementia
  • Alzheimer Disease
  • Circadian Rhythm Disorders
  • Circadian Rhythm Sleep Disorder
  • Insomnia
  • Hypersomnia
  • Cognitive Impairment
  • Cognitive Decline
  • Mild Cognitive Impairment
  • Frontotemporal Dementia
  • Neurocognitive Disorders
  • Vascular Dementia
  • Sleep Disorder
  • Memory Impairment

Keywords

  • Neuropsychiatric Behaviors
  • Agitation
  • Alzheimer's Disease
  • Dementia
03

In context

Dementia

2,230 studies on the registry are indexed under Dementia; 549 are open to participants now.

This study's enrollment of 421 is above the median of 83 across 1,669 interventional studies indexed under Dementia.

Browse Dementia studies →

Lead sponsor

University of Pennsylvania is the lead sponsor of 1,664 studies on the registry; 236 are open to participants now.

Of its 156 completed or terminated interventional studies of FDA-regulated products, 107 (69%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 110 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion criteria for care receiver (CR):

  1. be over age 60
  2. English speaking
  3. be able to tolerate wrist actigraphy (wear a watch on their wrist for a month)
  4. diagnosed with dementia using standard assessments and diagnostic criteria
  5. has CG reporting the presence of CRD symptoms
  6. If the CR is on any of four classes of psychotropic medications (antidepressant, benzodiazepines, antipsychotic, or anti-convulsant) or an anti-dementia medication (memantine or a cholinesterase inhibitor), we will require that the CR have been on a stable dose for 90 days prior to enrollment (typical time frame in clinical trials) to minimize possible confounding effects of concomitant medications

Inclusion criteria for caregiver (CG):

  1. CG is at least 18 years old
  2. CG lives close to the participant
  3. CG is planning to live in the area for at least 6 months
  4. If CG is on a psychotropic medication, CG must be on a stable dose for at least 60 days

Exclusion criteria for CR:

  1. deemed to be in a crisis/unsafe situation at baseline
  2. reported planned transition to another residential or care setting in less than 6 months
  3. at end-stage disease (defined as bed-bound and noncommunicative, or on hospice at baseline)
  4. currently enrolled in an interventional clinical trial for dementia or associated symptoms
  5. regular use of medications with substantial known effects on the measurement of HPA activity (e.g. corticosteroids, interferons, beta-blockers, cytotoxic chemotherapy)
  6. major surgery in the past 3 months
  7. history of major psychiatric and/or personality disorder
  8. history of heavy cigarette smoking (e.g. than 50 pack years)
  9. loss of a loved one in the past 3 months
  10. conditions known to affect measurement of circadian rhythm such as use of sedatives/ hypnotics, Huntington's disease, Cushing's disease, Addison's disease, normal pressure hydrocephalus, Parkinson's disease, advanced heart failure (New York Heart Stage 3-4), morbid obesity (BMI 35)
05

Study design

Phase
Phase 3
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
421 participants (actual)

Study arms

  • Experimental
    Timed Activity Intervention Protocol

    The timed activity group will involve 4 in-home visits and 4 brief telephone education sessions provided over 4 weeks. The timed activity intervention provides activities delivered at specific times in the daily cycle. The in-home sessions are spaced weekly so that the participants can have the opportunity to practice the activity with the interventionist and then on their own. During each session, the interventionist will reinforce activity use, review problem solving approaches, and provide education.

    Behavioral: Timed Activity Intervention

  • Active comparator
    Attention-Control Condition

    This condition will contain no active elements beyond its nonspecific components, and no theoretical basis to support an effect on CRDs. The attention-control group will also involve 4 in-home visits and 4 brief telephone education sessions. The attention control group will receive printed educational and training materials from the Alzheimer's Association and the NIH on home modification, health promotion, talking to your doctor, and advanced care planning that coincide with session content.

    Behavioral: Attention-Control Condition

Interventions

  • BehavioralAttention-Control Condition

    This condition will contain no active elements beyond its nonspecific components, and no theoretical basis to support an effect on CRDs. The attention-control group will also involve 4 in-home visits and 4 brief telephone education sessions. The attention control group will receive printed educational and training materials from the Alzheimer's Association and the NIH on home modification, health promotion, talking to your doctor, and advanced care planning that coincide with session content.

  • BehavioralTimed Activity Intervention

    The timed activity group will involve 4 in-home visits and 4 brief telephone education sessions provided over 4 weeks. The timed activity intervention provides activities delivered at specific times in the daily cycle. The in-home sessions are spaced weekly so that the participants can have the opportunity to practice the activity with the interventionist and then on their own. During each session, the interventionist will reinforce activity use, review problem-solving approaches, and provide education.

06

What researchers measure

Primary outcomes

  1. Change in the Quality of Life in Alzheimer's Disease (QOL-AD) Scale

    Person living with dementia quality of life. The QOL-AD scale uses a scale of 1-4 (poor, fair, good, or excellent) to rate a variety of life domains, including the patient's physical health, mood, relationships, activities, and ability to complete tasks. Total scores are calculated by summing all domain scores. The total score range is 13 to 52, with higher scores indicating higher quality of life. Total scores were analyzed to see if there was a change from baseline to one month. The change was calculated from two time points as the value at the later time point minus the value at the earlier time point. Change scores are reported.

    Time frame: Baseline and 1 month

Secondary outcomes

  1. Neuropsychiatric Inventory (NPI)

    Neuropsychiatric Behaviors The Neuropsychiatric Inventory Questionnaire (NPI) is an informant-based instrument that measures the presence and severity of 12 Neuropsychiatric Symptoms (NPS) in patients with dementia, as well as informant distress. Neuropsychiatric symptoms are rated by the caregiver within a domain in terms of both frequency (1=rarely, less than once per week; 2=sometimes, about once per week; 3=often, several times per week; and 4=very often, once or more per day) and severity (1=mild; 2=moderate; 3=severe), thus yielding a composite symptom domain score (frequency × severity) ranging from 0 (absence of behavioral symptoms) to 144 points (maximum severity of behavioral symptoms).

    Time frame: 4 Months

Other outcomes

  1. Circadian Rhythm Symptoms From Actigraphy

    Measured using a Motionlogger actigraphy bracelet worn by CR for consecutive 24-hour periods for one whole month. Actigraphic measures of physical activity do not rely on participant self-report and may be of particular importance for efforts to examine the health benefits of physical activity across the full spectrum of older individuals especially those with dementia, a group in which loss of motor function is particularly salient.

    Time frame: 30 days

07

Results

Posted Jul 26, 2024

Participant flow

Participant flow — Overall Study
MilestoneCaregivers of Persons Living With Dementia: Timed Activity Intervention ProtocolCaregivers of Persons Living With Dementia: Attention-Control ConditionPeople Living With Dementia: Timed Activity Intervention ProtocolPersons Living With Dementia: Attention-Control ConditionUnrandomized
Started1051051051051
Completed949594950
Not completed111011101
Withdrew: Lost to follow-up47471
Withdrew: Withdrawal by subject73730

Outcome measures

PrimaryChange in the Quality of Life in Alzheimer's Disease (QOL-AD) Scale

Person living with dementia quality of life. The QOL-AD scale uses a scale of 1-4 (poor, fair, good, or excellent) to rate a variety of life domains, including the patient's physical health, mood, relationships, activities, and ability to complete tasks. Total scores are calculated by summing all domain scores. The total score range is 13 to 52, with higher scores indicating higher quality of life. Total scores were analyzed to see if there was a change from baseline to one month. The change was calculated from two time points as the value at the later time point minus the value at the earlier time point. Change scores are reported.

Time frame:
Baseline and 1 month
Reported as:
Mean · scores on a scale
Change in the Quality of Life in Alzheimer's Disease (QOL-AD) Scale
scores on a scalePeople Living With Dementia: Timed Activity Intervention ProtocolPersons Living With Dementia: Attention-Control Condition
Change in the Quality of Life in Alzheimer's Disease (QOL-AD) Scale0.56 ± 4.06-0.47 ± 5.16
SecondaryNeuropsychiatric Inventory (NPI)

Neuropsychiatric Behaviors The Neuropsychiatric Inventory Questionnaire (NPI) is an informant-based instrument that measures the presence and severity of 12 Neuropsychiatric Symptoms (NPS) in patients with dementia, as well as informant distress. Neuropsychiatric symptoms are rated by the caregiver within a domain in terms of both frequency (1=rarely, less than once per week; 2=sometimes, about once per week; 3=often, several times per week; and 4=very often, once or more per day) and severity (1=mild; 2=moderate; 3=severe), thus yielding a composite symptom domain score (frequency × severity) ranging from 0 (absence of behavioral symptoms) to 144 points (maximum severity of behavioral symptoms).

Time frame:
4 Months

Results for this outcome have not been posted.

Other pre-specifiedCircadian Rhythm Symptoms From Actigraphy

Measured using a Motionlogger actigraphy bracelet worn by CR for consecutive 24-hour periods for one whole month. Actigraphic measures of physical activity do not rely on participant self-report and may be of particular importance for efforts to examine the health benefits of physical activity across the full spectrum of older individuals especially those with dementia, a group in which loss of motor function is particularly salient.

Time frame:
30 days

Results for this outcome have not been posted.

Adverse events

Collected over Adverse event data were collected during time of participant enrollment (one month of active participation, three-month follow-up after completion of study).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Unrandomized0/1 (0%)0/1 (0%)1/1 (100%)
People Living With Dementia: Timed Activity Intervention Protocol0/105 (0%)0/105 (0%)6/105 (5.7%)
Persons Living With Dementia: Attention-Control Condition0/105 (0%)0/105 (0%)5/105 (4.8%)
Caregivers of Persons Living With Dementia: Timed Activity Intervention Protocol0/105 (0%)0/105 (0%)0/105 (0%)
Caregivers of Persons Living With Dementia: Attention-Control Condition0/105 (0%)0/105 (0%)0/105 (0%)
Most frequent other events
Most frequent other events
EventUnrandomizedPeople Living With Dementia: Timed Activity Intervention ProtocolPersons Living With Dementia: Attention-Control ConditionCaregivers of Persons Living With Dementia: Timed Activity Intervention ProtocolCaregivers of Persons Living With Dementia: Attention-Control Condition
InfestationInfections and infestations1/10/1050/1050/1050/105
HospitalizationInjury, poisoning and procedural complications0/12/1054/1050/1050/105
FallInjury, poisoning and procedural complications0/11/1051/1050/1050/105
Caregiver agitationSocial circumstances0/11/1050/1050/1050/105
WanderingSocial circumstances0/11/1050/1050/1050/105
Lack of caregiver supportSocial circumstances0/11/1050/1050/1050/105

Baseline characteristics

Age, Continuous
Age, Continuous(years)People Living With Dementia: Timed Activity Intervention ProtocolPersons Living With Dementia: Attention-Control ConditionCaregivers of Persons Living With Dementia: Timed Activity Intervention ProtocolCaregivers of Persons Living With Dementia: Attention-Control ConditionTotal
Mean73.5 ± 8.473.9 ± 8.957.5 ± 14.255.6 ± 15.365.13 ± 11.7
Sex: Female, Male
Sex: Female, Male(Participants)People Living With Dementia: Timed Activity Intervention ProtocolPersons Living With Dementia: Attention-Control ConditionCaregivers of Persons Living With Dementia: Timed Activity Intervention ProtocolCaregivers of Persons Living With Dementia: Attention-Control ConditionTotal
Female67726772278
Male37333733140
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)People Living With Dementia: Timed Activity Intervention ProtocolPersons Living With Dementia: Attention-Control ConditionCaregivers of Persons Living With Dementia: Timed Activity Intervention ProtocolCaregivers of Persons Living With Dementia: Attention-Control ConditionTotal
Hispanic or Latino1821182178
Not Hispanic or Latino85838583336
Unknown or Not Reported11114
Race (NIH/OMB)
Race (NIH/OMB)(Participants)People Living With Dementia: Timed Activity Intervention ProtocolPersons Living With Dementia: Attention-Control ConditionCaregivers of Persons Living With Dementia: Timed Activity Intervention ProtocolCaregivers of Persons Living With Dementia: Attention-Control ConditionTotal
American Indian or Alaska Native00000
Asian00000
Native Hawaiian or Other Pacific Islander00000
Black or African American65706470269
White39344034147
More than one race00000
Unknown or Not Reported11114
08

Study locations

1 site
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
09

References and documents

Publications

  • Hodgson NA, Granger DA. Collecting saliva and measuring salivary cortisol and alpha-amylase in frail community residing older adults via family caregivers. J Vis Exp. 2013 Dec 18;(82):e50815. doi: 10.3791/50815. PubMed 24378361 ↗
  • Hodgson NA, Gitlin LN, Winter L, Czekanski K. Undiagnosed illness and neuropsychiatric behaviors in community residing older adults with dementia. Alzheimer Dis Assoc Disord. 2011 Apr-Jun;25(2):109-15. doi: 10.1097/WAD.0b013e3181f8520a. PubMed 20921879 ↗
  • Hodgson NA, Andersen S. The clinical efficacy of reflexology in nursing home residents with dementia. J Altern Complement Med. 2008 Apr;14(3):269-75. doi: 10.1089/acm.2007.0577. PubMed 18370580 ↗
  • Hirschman KB, Hodgson NA. Evidence-Based Interventions for Transitions in Care for Individuals Living With Dementia. Gerontologist. 2018 Jan 18;58(suppl_1):S129-S140. doi: 10.1093/geront/gnx152. PubMed 29361067 ↗
  • Samus QM, Black BS, Bovenkamp D, Buckley M, Callahan C, Davis K, Gitlin LN, Hodgson N, Johnston D, Kales HC, Karel M, Kenney JJ, Ling SM, Panchal M, Reuland M, Willink A, Lyketsos CG. Home is where the future is: The BrightFocus Foundation consensus panel on dementia care. Alzheimers Dement. 2018 Jan;14(1):104-114. doi: 10.1016/j.jalz.2017.10.006. Epub 2017 Nov 21. PubMed 29161539 ↗
  • Regier NG, Hodgson NA, Gitlin LN. Characteristics of Activities for Persons With Dementia at the Mild, Moderate, and Severe Stages. Gerontologist. 2017 Oct 1;57(5):987-997. doi: 10.1093/geront/gnw133. PubMed 27986794 ↗
  • Gitlin LN, Piersol CV, Hodgson N, Marx K, Roth DL, Johnston D, Samus Q, Pizzi L, Jutkowitz E, Lyketsos CG. Reducing neuropsychiatric symptoms in persons with dementia and associated burden in family caregivers using tailored activities: Design and methods of a randomized clinical trial. Contemp Clin Trials. 2016 Jul;49:92-102. doi: 10.1016/j.cct.2016.06.006. Epub 2016 Jun 21. PubMed 27339865 ↗
  • Hodgson NA, Gooneratne N, Perez A, Talwar S, Huang L. A timed activity protocol to address sleep-wake disorders in home dwelling persons living with dementia: the healthy patterns clinical trial. BMC Geriatr. 2021 Aug 3;21(1):451. doi: 10.1186/s12877-021-02397-2. PubMed 34344312 ↗
  • Hwang Y, Connell LM, Rajpara AR, Hodgson NA. Impact of COVID-19 on Dementia Caregivers and Factors Associated With their Anxiety Symptoms. Am J Alzheimers Dis Other Demen. 2021 Jan-Dec;36:15333175211008768. doi: 10.1177/15333175211008768. PubMed 33853394 ↗

Study documents

  • Protocol and statistical analysis plan · Nov 2, 2020

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03682185
Responsible party
Sponsor
First posted
Sep 24, 2018
Start date
May 1, 2016
Primary completion
May 31, 2021
Completion
May 31, 2021
Results posted
Jul 26, 2024
Last update
Jul 26, 2024

Study contacts

Nancy A. Hodgson
principal investigator · University of Pennsylvania

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion